Validation of the multidimensional impact of Cancer Risk Assessment Questionnaire to assess impact of waiting for genome sequencing results.

Best, M; Napier, C; Schlub, T; Bartley, N; Biesecker, B; Ballinger, M; Butow, P

Validation of the multidimensional impact of Cancer Risk Assessment Questionnaire to assess impact of waiting for genome sequencing results.

Best, M Napier, C Schlub, T Bartley, N

Biesecker, B Ballinger, M Butow, P

Permalink

Publisher:: Wiley
Publication Type:: Journal Article
Citation:: Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 2022, 31, (7), pp. 1204-1211
Issue Date:: 2022-07

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download full textAdobe PDF (303.43 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Best, M
dc.contributor.author	Napier, C
dc.contributor.author	Schlub, T
dc.contributor.author	Bartley, N https://orcid.org/0000-0001-9052-1616
dc.contributor.author	Biesecker, B
dc.contributor.author	Ballinger, M
dc.contributor.author	Butow, P
dc.date.accessioned	2022-12-01T02:37:39Z
dc.date.available	2022-02-18
dc.date.available	2022-12-01T02:37:39Z
dc.date.issued	2022-07
dc.identifier.citation	Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 2022, 31, (7), pp. 1204-1211
dc.identifier.issn	1057-9249
dc.identifier.issn	1099-1611
dc.identifier.uri	http://hdl.handle.net/10453/163987
dc.description.abstract	OBJECTIVE: To determine whether the existing Multidimensional Impact of Cancer Risk Assessment (MICRA) scale, which assesses impact of receiving genetic test results on individuals being assessed for cancer risk, can be successfully adapted to cancer patients experiencing prolonged waiting for results of germline genome sequencing (GS). METHODS: Patients previously diagnosed with likely hereditary cancer (n = 250) who were waiting for germline GS results completed questionnaires 3 months after baseline. We adapted the MICRA to measure anxiety associated with waiting for results, and assessed factor structure, internal consistency, test-retest reliability and construct validation. RESULTS: Factor analysis revealed four factors: distress, positive experience, family support and uncertainty. Internal consistency for each sub-scale was high with the values of Cronbach's alpha for the distress, positive experiences, family support and uncertainty sub-scales 0.92, 0.88, 0.92 and 0.87, respectively. Test-retest reliability was poor, with intra-class correlations of 0.53, 0.13, 0.33 and 0.52 for the four factors, respectively. Construct validation showed large correlations between the MICRA distress and uncertainty sub-scale scores and the Impact of Events score intrusion (0.42 and 0.62, respectively) and IES avoidant thinking sub-scales (0.40 and 0.58, respectively) but not the Hospital Anxiety and Depression Scale sub-scales. CONCLUSIONS: The adapted MICRA identified test-related anxiety and uncertainty in a population of cancer patients waiting for germline GS results. Results suggest that the distress and uncertainty sub-scales of the adapted measure are most useful in this context.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Wiley
dc.relation.ispartof	Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer
dc.relation.isbasedon	10.1002/pon.5908
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1103 Clinical Sciences, 1112 Oncology and Carcinogenesis, 1701 Psychology
dc.subject.classification	Oncology & Carcinogenesis
dc.subject.mesh	Anxiety
dc.subject.mesh	Humans
dc.subject.mesh	Neoplasms
dc.subject.mesh	Psychometrics
dc.subject.mesh	Reproducibility of Results
dc.subject.mesh	Risk Assessment
dc.subject.mesh	Surveys and Questionnaires
dc.subject.mesh	Anxiety
dc.subject.mesh	Humans
dc.subject.mesh	Neoplasms
dc.subject.mesh	Psychometrics
dc.subject.mesh	Reproducibility of Results
dc.subject.mesh	Risk Assessment
dc.subject.mesh	Surveys and Questionnaires
dc.subject.mesh	Humans
dc.subject.mesh	Neoplasms
dc.subject.mesh	Risk Assessment
dc.subject.mesh	Reproducibility of Results
dc.subject.mesh	Anxiety
dc.subject.mesh	Psychometrics
dc.subject.mesh	Surveys and Questionnaires
dc.title	Validation of the multidimensional impact of Cancer Risk Assessment Questionnaire to assess impact of waiting for genome sequencing results.
dc.type	Journal Article
utslib.citation.volume	31
utslib.location.activity	England
utslib.for	1103 Clinical Sciences
utslib.for	1112 Oncology and Carcinogenesis
utslib.for	1701 Psychology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
utslib.copyright.status	open_access	*
pubs.consider-herdc	false
dc.date.updated	2022-12-01T02:37:33Z
pubs.issue	7
pubs.publication-status	Published
pubs.volume	31
utslib.citation.issue	7

Abstract:

OBJECTIVE: To determine whether the existing Multidimensional Impact of Cancer Risk Assessment (MICRA) scale, which assesses impact of receiving genetic test results on individuals being assessed for cancer risk, can be successfully adapted to cancer patients experiencing prolonged waiting for results of germline genome sequencing (GS). METHODS: Patients previously diagnosed with likely hereditary cancer (n = 250) who were waiting for germline GS results completed questionnaires 3 months after baseline. We adapted the MICRA to measure anxiety associated with waiting for results, and assessed factor structure, internal consistency, test-retest reliability and construct validation. RESULTS: Factor analysis revealed four factors: distress, positive experience, family support and uncertainty. Internal consistency for each sub-scale was high with the values of Cronbach's alpha for the distress, positive experiences, family support and uncertainty sub-scales 0.92, 0.88, 0.92 and 0.87, respectively. Test-retest reliability was poor, with intra-class correlations of 0.53, 0.13, 0.33 and 0.52 for the four factors, respectively. Construct validation showed large correlations between the MICRA distress and uncertainty sub-scale scores and the Impact of Events score intrusion (0.42 and 0.62, respectively) and IES avoidant thinking sub-scales (0.40 and 0.58, respectively) but not the Hospital Anxiety and Depression Scale sub-scales. CONCLUSIONS: The adapted MICRA identified test-related anxiety and uncertainty in a population of cancer patients waiting for germline GS results. Results suggest that the distress and uncertainty sub-scales of the adapted measure are most useful in this context.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/163987